Life Science Start-Ups: Tech Transfer Deals, March 2014
This article was originally published in Start Up
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.
You may also be interested in...
AbbVie has in-licensed Lupin’s MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) inhibitor program for over $900m in potential milestone payments, bringing Christmas cheer for the Indian firm. The deal terms for the preclinical asset are rather striking.
BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.